Related Experiment Videos
A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study
H S Maurer1, J D Lloyd-Still, C Ingrisano
1Division of Hematology, Children's Memorial Hospital, Northwestern University Medical School, Chicago, Illinois.
Insights
Early iron chelation therapy is crucial for children with beta-thalassemia major. Starting treatment before age 3 may prevent liver fibrosis and growth issues, improving long-term outcomes.
Area of Science:
- Hematology
- Pediatric Medicine
- Hepatology
Background:
- Transfusion-dependent beta-thalassemia major leads to iron overload.
- Iron overload causes significant complications, including liver fibrosis and growth impairment.
- Deferoxamine (desferrioxamine) is a primary chelation therapy.
Purpose of the Study:
- To prospectively evaluate the efficacy of deferoxamine in reducing hepatic iron in pediatric patients with beta-thalassemia major.
- To assess the impact of chelation therapy on liver histology, iron levels, and growth.
- To determine the optimal age for initiating chelation therapy to prevent long-term complications.
Main Methods:
- Prospective study of 16 pediatric patients (3-17 years) with transfusion-dependent beta-thalassemia major.
- Liver biopsy at study onset and periodically thereafter to assess histology and iron content.
- Monitoring of serum ferritin levels and iron excretion during deferoxamine chelation therapy.
- Assessment of linear growth patterns throughout the study period.
Main Results:
- Initial liver biopsies revealed marbled fibrosis in 14 of 16 patients.
- Substantial reduction in hepatic iron concentration observed in most patients.
- Limited improvement in hepatic fibrosis noted in only 2 of 7 patients after 3-5 years.
- Growth impairment observed in patients starting around age 10, despite chelation.
- Cardiac disease led to death in two older patients (18 and 22 years).
Conclusions:
- Early initiation of deferoxamine chelation therapy, ideally before age 3, is essential.
- Early treatment may prevent or mitigate severe liver fibrosis and growth impairment.
- Timely intervention is critical for improving long-term health outcomes in beta-thalassemia major.
Abstract:
Sixteen patients (age range, 3 to 17 years) with transfusion-dependent beta-thalassemia major were studied prospectively, beginning at the onset of chelation therapy with deferoxamine (desferrioxamine). A liver biopsy specimen was obtained from each patient at the start of the study, and periodically thereafter. Liver histologic features, iron content, and iron excretion were assessed during the course of the study. Hepatic iron levels from liver biopsy specimens appeared to correlate well with serum ferritin levels in the younger less heavily iron-loaded patients; however, in patients with higher serum ferritin levels, hepatic iron appeared to reach a saturation level. Fourteen of the 16 patients showed a pattern of marbled fibrosis of the liver in their initial biopsy specimens. Follow-up biopsy specimens from nearly all of the patients showed a substantial reduction in iron concentration, but only two of seven patients showed improvement in the degree of hepatic fibrosis three to five years later. Patients less than 8 years old exhibited a normal pattern of linear growth until approximately the age of 10 years, followed by a progressive decrease to the 30th to 40th percentile. Two patients, aged 18 and 22 years, died of cardiac disease during the study. These findings suggest that chelation therapy in patients with transfusion-dependent thalassemia needs to be initiated at an early age, possibly before 3 years, if significant liver fibrosis and growth impairment are to be effectively prevented.